Spotlighting the complex ballet of cancer cell death
When he was an undergraduate at the University of Colombo in Sri Lanka, Nishanth Kuganesan undertook a solo study probing the impact of radiation treatments on chromosomes in lymphocytes, a family of white blood cells in the immune system. The small-scale study of blood samples had measurable results: He found evidence of cellular damage. And he also found a career path: research on the biology of cancer.
Kuganesan, who said he has been “very passionate about science” since his boyhood, is now a fifth-year doctoral student at the University of Toledo. Come April, he is set to defend his dissertation, which details nuances of ferroptosis, such as the critical roles of the gene TP53, dubbed the “guardian of the genome,” and the retinoblastoma/E2F checkpoint in curbing cancer.
As he considers his future, this Ph.D. candidate in cell and molecular biology dreams of making a difference in battling disease. “I really want to be in research and development … either in academia or in industry,” Kuganesan said.
He credits his advisor William Taylor, professor and associate chair of the biological sciences department at the University of Toledo, for providing him with room to grow as a scientist. “He has given me a lot of freedom to explore in his lab,” Kuganesan said.
There, Kuganesan discovered several new steps in the biochemical ballet of ferroptosis. “It didn’t make sense at the beginning,” he recalled.
But the pieces fell into place, and as first author of the paper based on his team’s work on the tumor suppressor p53, Kuganesan received a 2023 JBC Herbert Tabor Early Career Investigator Award.
Beyond the thrill of new knowledge, Kuganesan’s award-winning research on the intricate cellular dance of tumor suppression could help refine future steps in chemotherapy, he said.
“Our findings will help drug makers be cautious when they are making therapeutic drugs.”
No longer a linear pathway
Early in their study of the programmed cell death known as ferroptosis, Nishanth Kuganesan and his collaborators found that high levels of the tumor protein p53 heighten the destruction of cancer cells. Yet p21, a protein also known as cyclin-dependent kinase inhibitor 1, reins in ferroptosis. And they discovered something else: Overexpression of E2F, a family of genes that helps code for cell growth, also suppresses ferroptosis, with the involvement of p21.
E2F performs dual roles on the cellular stage. “E2F is essential for cells to function,” Kuganesan said. “In most cancer cells, it’s more than what’s needed, and this is the problem.”
Meanwhile, cyclin-dependent kinases and retinoblastoma proteins also play a part, stepping up to bar cancer cell death. Taken as a whole, the team’s recent study spotlights the complex interplay of the factors in ferroptosis. It’s as if several sets of conflicting choreography were being danced on the stage of tumor suppression.
“The whole thing was kind of unexpected,” Kuganesan said. “The linear pathway of the cell cycle in ferroptosis is not linear anymore.”
During the study, L.M. Viranga Tillekeratne, a University of Toledo professor of medicinal and biological chemistry, led the synthesis of CETZOLE-1, a novel small molecule. Kuganesan and his team used that substance to discover the mechanism of ferroptosis.
“,” appeared in the Journal of Biological Chemistry in December 2021. Kuganesan and other winners of the JBC Tabor Award will give talks during a symposium on Sunday, March 26, at Discover BMB in Seattle.
Enjoy reading 91影库Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91影库Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles
Fliesler wins scientific and ethical awards
He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.
Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥� to help the patients who need it most.
Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥� and just getting started.
91影库members recognized as Allen investigators
Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.
AI can be an asset, 91影库educators say
Pedagogy experts share how they use artificial intelligence to save time, increase accessibility and prepare students for a changing world.
91影库undergraduate education programs foster tomorrow鈥檚 scientific minds
Learn how the society empowers educators and the next generation of scientists through community as well as accreditation and professional development programs that support evidence-based teaching and inclusive pedagogy.